Disease · EFO_0009855
frontal fibrosing alopecia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. frontal fibrosing alopecia. Diseases, record EFO_0009855. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0009855
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- frontal fibrosing alopecia
- Open Targets ID
- EFO_0009855
- Highest stage of its drugs
- Phase 2, for 3 of its 8 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs8
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DELGOCITINIB | CHEMBL4297507 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DEUCRAVACITINIB | CHEMBL4435170 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NALTREXONE | CHEMBL19019 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HYDROXYCHLOROQUINE | CHEMBL1535 | Small molecule | Unknown | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| METHOTREXATE | CHEMBL34259 | Small molecule | Unknown | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CYCLOSPORINE | CHEMBL160 | Protein | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TOFACITINIB | CHEMBL221959 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TRETINOIN | CHEMBL38 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
Targets14
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| TYK2 | Janus Kinase (JAK) | 3 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/7297 | Drugs and targets |
| JAK1 | Janus Kinase (JAK) | 2 | Janus Kinase (JAK) inhibitor | Phase 2 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK2 | Janus Kinase (JAK) | 2 | Janus Kinase (JAK) inhibitor | Phase 2 | https://conductscience.org/library/genes/3717 | Drugs and targets |
| JAK3 | Janus Kinase (JAK) | 2 | Janus Kinase (JAK) inhibitor | Phase 2 | https://conductscience.org/library/genes/3718 | Drugs and targets |
| DHFR | Dihydrofolate reductase | 1 | Dihydrofolate reductase inhibitor | Unknown | https://conductscience.org/library/genes/1719 | Drugs and targets |
| OPRD1 | Opioid receptors; mu/kappa/delta | 1 | Opioid receptors; mu/kappa/delta antagonist | Phase 2 | https://conductscience.org/library/genes/4985 | Drugs and targets |
| OPRK1 | Opioid receptors; mu/kappa/delta | 1 | Opioid receptors; mu/kappa/delta antagonist | Phase 2 | https://conductscience.org/library/genes/4986 | Drugs and targets |
| OPRM1 | Opioid receptors; mu/kappa/delta | 1 | Opioid receptors; mu/kappa/delta antagonist | Phase 2 | https://conductscience.org/library/genes/4988 | Drugs and targets |
| PPIA | Peptidyl-prolyl cis-trans isomerase A | 1 | Cyclophilin A modulator | Unknown | https://conductscience.org/library/genes/5478 | Drugs and targets |
| RARA | Retinoic acid receptor | 1 | Retinoic acid receptor agonist | Unknown | https://conductscience.org/library/genes/5914 | Drugs and targets |
1 to 10 of 14
See all 14 targetsTrials6
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04409041 | Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia | Phase 2 | 43 | 2021-12-30 | Lichen Planopilaris, Frontal Fibrosing Alopecia | NALTREXONE | Its record names the disease | ClinicalTrials.gov |
| NCT05332366 | A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia | Phase 2 | 35 | 2025-02-07 | Frontal Fibrosing Alopecia | DELGOCITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT06202560 | Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study | Not applicable | 11 | 2025-05-30 | Frontal Fibrosing Alopecia, Lichen Planopilaris of Scalp | TOFACITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT06512766 | a Retrospective Study on the Systemic Treatment of LPP and FFA | 315 | Cicatricial Alopecia, Lichen Planopilaris, Lichen Plano-Pilaris, Frontal Fibrosing Alopecia, Hair Diseases, Scarring Alopecia, Hair Loss/Baldness | CYCLOSPORINE, HYDROXYCHLOROQUINE, METHOTREXATE | Its record names the disease | ClinicalTrials.gov | ||
| NCT07190534 | The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial) | 50 | Frontal Fibrosing Alopecia, Cicatricial Alopecia | HYDROXYCHLOROQUINE, METHOTREXATE | Its record names the disease | ClinicalTrials.gov | ||
| NCT07508488 | Deucravacitinib in the Treatment of Cicatricial Alopecias | Phase 2 | 20 | Central Centrifugal Cicatricial Alopecia, Frontal Fibrosing Alopecia | DEUCRAVACITINIB | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials1
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it |
|---|---|---|
| 41101628 | DERIVED | 1 |
Source PubMed
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0009855
GET https://conductscience.org/api/diseases/v1/EFO_0009855/drugs